Original Research

More Original Research
Novel Formulation of THC and CBN in a Repeat-Action Tablet Improves Objective and Subjective Measurements of Sleep

he aim of this study was to evaluate the effect of a repeat-action tablet containing 10 mg THC and 5 mg CBN on sleep quality, sleep duration, and awakenings in participants (medical cannabis users). The effect of the combination tablet was evaluated using objectively measured and self-reported data.

Positive Autism Intervention With Cannabidiol: A Case Study

Nearly 1 in 59 children in the United States has been identified with autism spectrum disorder (ASD), according to the latest estimates from the Centers for Disease Control and Prevention. This case describes success with daily use of hemp-extracted cannabidiol (CBD) with low psychoactive delta-9-tetrahydrocannabinol (THC) in a young boy diagnosed with DSM-5 ASD.

Psychiatry News

PAREA Promotes Psychedelic Access and Research Across Europe
Patient advocacy groups, psychedelic foundations, and scientific organizations across the EU have banded together to form the Psychedelic Access and Research European Alliance (PAREA).
Psilocybin Shows Promising and Sustained Antidepressant Effects in Patients With Major Depressive Disorder
One 25-mg dose of psilocybin administered with psychological support is enough to cause a “large, rapid, powerful drop” in depressive symptoms among patients with major depressive disorder.
California State Assembly Passes Bill Legalizing Psychedelics
Lawmakers in California have passed Senate Bill 58 (SB 58) legalizing possession, cultivation, and use of limited amounts of mescaline, dimethyltryptamine (DMT), psilocybin, and psilocin. The bill, introduced by California Senator Scott Wiener and reported in Forbes, underwent significant amendments that now need to be approved by the Senate and then the state governor, Gavin…
Men With Cannabis Use Disorder May Be More Susceptible To Schizophrenia Than Women
A Danish cohort study led by the National Institute on Drug Abuse and the Mental Health Services shows that young men with cannabis use disorder (CUD) are at increased risk for developing schizophrenia. The nationwide registry study, published in Psychological Medicine, examined the health records of > 6 million people in Denmark over the course…
Full-Spectrum, High-CBD Sublingual Formulation Reduces Anxiety in Phase 2 Study
Results from a recent study provide preliminary evidence that a full-spectrum, high-cannabidiol (CBD) product can be an effective and well-tolerated treatment for anxiety. The study, published in Community Medicine, found high rates of adherence, no intoxication, and no serious adverse events occurred. A team of researchers from Harvard Medical School conducted a study with 14…
Medical Cannabis May Improve Quality of Life and General Health
A new Australian study suggests that the use of medical cannabis by patients with chronic pain, anxiety, posttraumatic stress disorder, and multiple sclerosis may be associated with improved mood and sleep, better quality of life, and improved general health. The study, published in Drug Science, Policy, and Law, notes the collection of real-world data on…